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Abstract
Background: Interferon gamma release assays (IGRA) are replacing the tuberculin skin test (TST) as a diagnostic tool for
Mycobacterium tuberculosis infection. However research into the test’s performance in the high HIV-TB burden setting is
scarce. This study aimed to define the sensitivity of an IGRA, QuantiFERON-TBH Gold In-Tube (QGIT), in adult Zambian
patients with active smear-positive tuberculosis. Secondary outcomes focussed on the effect of HIV on the test’s
performance.
Principal Findings: Patients attending government health clinics were recruited within 1 month of starting treatment for TB.
Subjects were tested with QGIT and TST. T lymphocyte counts were estimated (CD3
+, CD4
+, CD8
+). QGIT was performed for
112 subjects. 83/112 were QGIT positive giving an overall sensitivity of 74% [95%CI: 66,82]. A marked decrease in sensitivity
was observed in HIV positive patients with 37/59 (63%) being QGIT positive compared to 31/37 (84%) HIV negative patients
[chi
2 p=0.033]. Low CD4
+ count was associated with increases in both indeterminate and false-negative results. Low CD4
+
count in combination with high/normal CD8
+ count was associated with false-negative results. TST was recorded for 92
patients, 62/92 were positive, giving a sensitivity of 67% [95%CI: 58,77]. Although there was little difference in the overall
sensitivities, agreement between TST and QGIT was poor.
Conclusions: QGIT was technically feasible with results in HIV negative subjects comparable to those achieved elsewhere.
However, where under-treated HIV is prevalent, an increased proportion of both indeterminate and false-negative QGIT
results can be expected in patients with active TB. The implications of this for the diagnosis of LTBI by QGIT is unclear. The
diagnostic and prognostic relevance of IGRAs in high burden settings needs to be better characterised.
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Introduction
Infection with Mycobacterium tuberculosis (MTB) results in nine
million new cases of tuberculosis disease (TB) and just under two
million deaths a year [1] The vast majority of TB is found in
South-East Asia, Africa and the western Pacific regions. However,
it is only in the African region and particularly in eastern and
southern Africa that the incidence continues to rise. This increase
is fuelled by the dual epidemic of TB and HIV and poses
considerable challenges for TB control [2]. Strengthening DOTS
and improving anti-retroviral therapy (ART) services are essential
[3]. Improving detection and treatment of latent tuberculosis
infection (LTBI) is also important.
The natural history of TB is altered in the presence of HIV
infection. The risk of both primary progressive disease and
reactivation of latent tuberculosis infection (LTBI) is increased,
resulting in a high incidence of active disease in this population
[4,5]. There is also an increased proportion of smear negative
disease [6]. The detection and treatment of LTBI with isoniazid
has proven efficacy in reducing incidence of active disease but as a
policy is poorly implemented [7,8]. One barrier to the effective
management of LTBI is a lack of accurate diagnostic tools.
MTB is a slowly multiplying, intracellular pathogen that is
capable of surviving for many years in an immunocompetent
human host. As bacterial load is low in LTBI, conventional
microbiology has little to offer to aid diagnosis [9]. The tuberculin
skin test (TST) has been the most extensively used immune-based
test. A positive TST has clear association with an increased risk of
developing active tuberculosis. If used as a screening test, isoniazid
preventative therapy has greatest effect in a population who are
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non-tuberculous mycobacteria, use of BCG and immunosuppres-
sion have been identified as influencing the test outcome [11]. In
particular the test has a much lower sensitivity in HIV positive
patients [12].
Western medicine has incorporated interferon-gamma release
assays (IGRAs) into everyday practice and there is a growing
literature characterising their performance in this setting [13]. In
contrast, there is a scarcity of data from low income, high burden
countries. In the absence of a gold standard LTBI diagnostic, active
TB has been used as a surrogate in order to estimate the sensitivity of
IGRAs. Only two studies from Africa have been published that use
this approach. In a township in Cape Town where between 55 and
61% of TB patients are thought to be HIV infected, 100/154 (65%)
culture positive TB patients were QuantiFERON-TBH Gold In-
Tube (QGIT) positive [14]. Only 41 patients knew their HIV status,
of these, 17/26 (65%) HIV positive subjects had a positive IGRA
result compared with 11/15 (73%) HIV negative. Those that were
HIV positive had lower responses to TB antigens and all 5
indeterminate QGIT results occurred in the HIV positive group.
As part of a larger study in The Gambia, 80 recently diagnosed
culture positive TB patients were recruited [15]. 7/80 (8.8%) were
HIV positive. The authors report results for 75 subjects of whom 48
were QGIT positive giving a sensitivity of 64.0% (95%CI: 51,73).
The only other study from a high burden area reports QGIT results
for 60 pulmonary TB patients of whom 97% were culture positive
and 5% HIV positive [16]. Their interferon-gamma responses were
then followed through the course of TB treatment. Prior to treatment,
44/60 (73%) were QGIT positive. Responses fluctuated over the
following six months but with no significant change in overall
sensitivity.
In this study, we aimed to define the sensitivity of QGIT in
Zambian adults with smear positive TB, focussing on the effect of
HIV infection on the test’s performance.
Methods
Study Population
The study was conducted in the government clinics of the four
Zambia and South Africa tuberculosis and AIDS reduction study
(ZAMSTAR) sites in Lusaka. In 2004, Zambia reported the sixth
highest notification rate in Africa with 471 new or relapsed cases
per 100 000 population. The true incidence is estimated to be over
600 per 100 000. HIV prevalence among pregnant women in
urban areas is greater than 20%, with an estimated prevalence of
HIV among adult TB cases of 54% [17]. The study protocol was
approved by London School of Hygiene and Tropical Medicine
ethics committee and by the University of Zambia ethical research
committee.
Eligibility & Recruitment
Recruitment occurred over the period of July to October 2007.
The target population was all patients recorded as smear positive
over the age of 18 within one month of commencing treatment.
Patients were defined as smear positive if acid-fast bacilli were
detected by direct light microscopy in at least one sputum smear.
These patients are required to attend clinic daily for observed
therapy. Eligible patients were identified through the review of
patient-held treatment cards on arrival at clinic. In exceptional
circumstances due to infirmity or work commitments a surrogate
collects daily drugs for the patient or a week’s supply is given. No
efforts were made to trace non-attenders or defaulters, however,
we attempted to identify and capture weekly attenders by
reviewing clinic-held treatment cards.
Venepuncture
Venous blood was obtained by needle and syringe and
immediately transferred to evacuated blood collection tubes that
were inverted 8 times to thoroughly mix contents. Nursing staff in
Lusaka had previously reported problems with slow and
incomplete filling of QGIT tubes (manufactured by Becton,
Dickinson and company - BD, Franklin Lakes, USA, supplied by
Cellestis, Carnegie, Australia) using the vacutainer system alone.
This is presumably due to the small volume and relatively low
negative pressure in the tubes compared to the ambient pressure in
Lusaka at around 1300 m above sea level. By using a syringe,
correct filling was ensured so that each of the QGIT tubes received
1 ml and the K2EDTA tube (BD) for T lymphocyte estimations at
least 1 ml. The full set of three QGIT tubes was used comprising
one coated with each of TB RD1 test antigens, PHA as a positive
control or heparin for the negative control. Blood collection
occurred between 08:00 and 12:00 with all QGIT samples placed
simultaneously at 12:00 in a portable incubator (Cellestis)
preheated to 37uC.
TST
TST was placed according to the Mantoux method using two
tuberculin units PPD RT23 in 0.1 ml Tween-80 (Statens Serum
Institut, Copenhagen, Denmark) [18]. Transverse induration was
measured in millimetres using callipers on one occasion between
48 and 164 hours after placement. This wide window for reading
was used in an attempt to improve capture and has been shown to
give reasonably reliable results [19]. In patients with TB and HIV,
cutaneous anergy is thought to be an all or nothing effect and so
there may be little gain in terms of reducing false-negative TST
results by lowering the cut-off from 10 mm to 5 mm [20].
However standard practice and is to use the 5 mm cut-off in HIV
positive patients. As all of our subjects had active TB and the
majority were expected to be HIV positive, the 5 mm cut-off was
used to define a positive TST in the main analysis. A secondary
analysis applied the 10 mm cut-off for comparison.
Laboratory Procedures
T lymphocyte estimations were performed within eight hours of
sampling. CD3
+, CD4
+ and CD8
+ were measured by flow
cytometry (FACSCount, BD) according to the manufacturer’s
instructions using standard reagents (BD). On arrival in the
laboratory, and after no more than 2 hours from the start of
incubation, QGIT samples were transferred to a Jouan incubator
(Thermo Fisher Scientific, Waltham, USA) to complete 24 hours
at 37uC. Samples were then returned to room temperature and,
after no more than 2 hours, centrifuged for 10 mins at 2200 RCF
(Thermo). Plasma was extracted and transferred to 220uC.
ELISA was performed precisely according to manufacturer’s
instructions using standard kits (Cellestis). Data acquired was
transferred to QuantiFERON-TBH Gold analysis software
(Cellestis) for results calculation.
Analysis of QGIT cut-off value
To calculate QGIT results, a value is calculated for the
concentration of IFN-gamma in the TB antigen tube minus the
corresponding concentration in the nil tube to take into account
background IFN-gamma level. The cut-off value for positive
results is set by the manufacturer at $0.35 IU/ml. It is possible
that this cut-off is not appropriate in all populations. In particular
it has been suggested that a lower cut-off may be appropriate in
populations where TB is prevalent and in HIV infected patients
with reduced T lymphocyte counts [21]. A lower cut-off value was
Low CD4 Compromises Assay
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2489suggested for South Korea by these investigators following receiver
operating characteristic (ROC) analysis of their data. Although
none of their subjects were HIV positive 29 of 87 were classified as
immunocompromised. A study of untreated culture-confirmed
cavitary pulmonary tuberculosis patients in Turkey also found that
reducing the cut-off to between 0.05 and 0.10 IU/ml improved
sensitivity with little effect on specificity [22]. The main analysis
for this study uses the manufacturer’s suggested cut-off of $0.35
IU/ml. A sub-analysis was performed to assess the impact of
lowering the cut-off to $0.13 IU/ml.
Data Handling
Data were analysed in STATA v.10 (StataCorp LP, Texas,
USA). When calculating sensitivity some authors have been
tempted to disregarded indeterminate results labelling them as
uninterpretable [14]. This definition artificially inflates the test
sensitivity and is less applicable on the population level.
Furthermore, if better understood, indeterminate results may also
be able to provide important clinical information on a personal
level. Sensitivity was therefore defined as number of positive results
over total number tested.
Results
Subject characteristics
112 adults with smear-positive tuberculosis were recruited
(table 1). 71 (63%) were male, median age was 31 (range: 18,58;
IQR: 25,36). 40 (36%) had sputum smear recorded as 1+,1 8
(16%) as 2+ and 53 (47%) as 3+, 1 (1%) was unknown. 20 (18%)
were relapse cases. 30 (27%) had received no treatment, 60 (54%)
were in the first two weeks of treatment and the remaining 21
(19%) had had between 2 and four weeks. 96 subjects had HIV
status recorded, of these, 59 (61%) were HIV positive. 105 subjects
had T-lymphocyte estimations performed. Median CD4
+ count
overall was 316 cells/ml (range: 6,1708; IQR: 170,594), dropping
to 212 cells/ml (range: 6,1015; IQR: 109,332) in those recorded as
being HIV positive and with a broad range in the HIV negative
subjects (median 542; range: 84,1708, IQR: 437,698). Median
body mass index (BMI) was 19 (range:13,25; IQR: 17,21).
QGIT
83/112 were QGIT positive giving an overall sensitivity of 74%
(95%CI: 66,82). Of the remainder, 13 (12%) had negative and 16
(14%) indeterminate results (table 2). In subjects recorded as being
HIV negative, 31/37 were QGIT positive giving a sensitivity of
84% (95%CI: 71,96). Among the HIV positive subjects, sensitivity
was significantly reduced to 63% (95%CI: 50,75), 37/59 being
QGIT positive with a marked increase in the proportion of
negative results (Pearson’s chi
2, 2df, p=0.033).
A low CD4
+ count has previously been shown to reduce the
sensitivity of QGIT [5,23]. To explore this effect, data were
stratified according to CD4
+ count. ,100 cells/ml represents a
very low CD4
+ count, ,200 is AIDS defining, 350 is the lower end
of the normal range for men. With falling CD4
+ count there was a
decrease in sensitivity of QGIT with relative increases in both
negative and indeterminate results (Pearson’s chi
2, 6df, p,0.001).
This was particularly marked at counts less than 100 cells/ml,
where only 3/13 (23%) had a positive QGIT result (figure 1).
The time on treatment was not seen to alter the proportion of
results in each category (Pearson’s chi
2, 2df, p=0.377; table 2).
For further analysis of factors affecting sensitivity, QGIT result
was transformed to a binary variable by combining negative and
indeterminate results. In order to increase statistical power,
continuous variables were redefined as dichotomous variables
using the following arbitrary cut-off values: age 31 years (median
of study population), BMI 18.5 kg/m
2 (World Health Organisa-
tion definition of malnutrition in adults), CD4
+ count 200 cells/ml
(AIDS defining), TB treatment period of 2 weeks.
In univariate analysis, a CD4 count greater than 200 cells/ml
was the only variable to show a significant association with positive
Table 1. Summary demographic and clinical characteristics of
subjects.
Variable Subcategory n/N (%) or Median (IQR)
Sex Male 71/112 (63)
Smear grade 1
+ 40/111 (36)
2
+ 18/111 (16)
3
+ 53/111 (48)
Unknown 1/112 (1)
BCG scar Present 71/109 (65)
Unknown 3/112 (3)
HIV status Positive 59/96 (61)
Unknown 16/112 (14)
ART Started 14/112 (13)
TB treatment period None 30/111 (27)
1 to 14 days 60/111 (54)
15 to 31 days 21/111 (19)
Relapse case 20/112 (18)
Age, years 31 (25,36)
BMI, kg/m
2 19 (17,21)
CD3
+, cells/ml 1112 (808,1687)
CD8
+, cells/ml 715 (344, 1028)
CD4
+, cells/ml Overall 316 (170,594)
HIV negative 542 (437,698)
HIV positive 212 (109,332)
ART, antiretroviral therapy; BMI, body mass index.
doi:10.1371/journal.pone.0002489.t001
Figure 1. Distribution of QuantiFERON-TBH Gold In-Tube
results by CD4
+ lymphocyte count. Proportion of both negative
and indeterminate results increased with falling CD4
+ lymphocyte
count. QGIT, QuantiFERON-TBH Gold In-Tube.
doi:10.1371/journal.pone.0002489.g001
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status, relapse cases, treatment period and BMI (OR 4.71; 95%CI:
1.74,12.60; table 3).
Although a low CD4
+ count was associated with both negative
and indeterminate results (median 144, 181 cells/ml respectively;
Wilcoxon p=0.710), CD8
+ count was high/normal in those with
negative results but low in those with indeterminate results
(median 999, 369 cells/ml respectively; Wilcoxon p=0.017;
figure 2).
TST
92 subjects had a TST result recorded (figure 3). 81/92 were
recorded within the standard 48–72 hour period, 9/92 at 96 hours
and 2/92 at 120 hours. Using a cut-off of 5 mm or more, 62/92
were TST positive, giving a sensitivity of 67% (95%CI: 58,77;
table 4). There was no evidence of loss of TST sensitivity at
.72 hours with 10/11 late readings being positive. 78 subjects had
both known HIV status and a TST result. The test was impaired in
HIV positive subjects with only 26/47 (55%) having a positive TST
compared to 25/31 (81%) in the HIV negative group (Pearson’s
chi
2, 1df, p=0.021). A CD4
+ count of less than 200 was clearly
associated with negative TST (p,0.001). Presence of a BCG scar
was not associated with variation in TST result (p=0.264).
There was no significant difference between the overall
sensitivities of TST and QGIT (McNemar’s, p=0.055). Although
clearly affected by some of the same factors, agreement between
the two tests was poor (agreement 64%, kappa 0.09; table 4).
There was no improvement if only HIV negative subjects or those
with CD4
+ count.200 were included (agreement, kappa: 68%,
20.18; 77%, 20.01 respectively). Negative TST result was not
particularly associated with either negative or indeterminate
QGIT results (Pearson’s chi
2, 2df, p=0.599; table 2).
Using a 10 mm cut-off, 48/92 were TST positive giving a reduced
overall sensitivity of 52% (95%CI: 42,63; table 4). This sensitivity was
significantly lower than QGIT’s (McNemar’s, p,0.001) and
agreement remained poor (agreement 55%, kappa 0.08).
Cut-off value for QGIT
Applying the cut-off suggested by Harada et al of $0.13 IU/ml
to our data [21], 5 negative and 4 indeterminate results would
have been reclassified as positive. All but one of these subjects were
HIV positive. This adjustment would bring the overall sensitivity
up to 82% (95% CI: 75,89). With the high background prevalence
of LTBI in Zambia, it was deemed inappropriate to attempt to
estimate IGRA specificity. Population specific ROC analysis could
not be performed to determine the cost in terms of reduced
specificity. No adjustment to the mitogen cut-off defining
indeterminate results has been suggested.
Discussion
This study investigated the performance of QGIT in a
population with high TB incidence and HIV prevalence. As no
gold standard exists for the diagnosis of LTBI, Pai et al
recommend the use of microbiologically confirmed tuberculosis
cases as an essential step in the assessment of new diagnostic tests
[24]. This approach was taken, recruiting adult smear-positive TB
patients into a cross-sectional study. QGIT was compared to TST
as well as smear microscopy. The aim of the study was not to
evaluate QGIT as a diagnostic test for active TB, but to increase
understanding of the test’s performance in this population by using
active TB as a surrogate for LTBI.
Table 2. Distribution of QuantiFERON-TBH Gold In-Tube
results by HIV status, CD4
+ lymphocyte count, treatment
period and TST result.
QGIT result, n/Nrow (%)
Positive Negative Indeterminate
Overall 83/112 (74) 13/112 (12) 16/112 (14)
HIV Status Negative 31/37 (84) 1/37 (3) 5/37 (13)
Positive 37/59 (63) 12/59 (20) 10/59 (17)
Unknown 15/16 (94) 0/16 (0) 1/16 (6)
CD4
+ count, cells/ml Less than 100 3/13 (23) 4/13 (31) 6/13 (46)
100 to 199 14/20 (70) 3/20 (15) 3/20 (15)
200 to 349 17/23 (74) 3/23 (13) 3/23 (13)
350 or more 43/49 (88) 2/49 (4) 4/49 (8)
Unknown 6/7 (86) 1/7 (14) 0/7 (0)
Treatment period 0 days 21/30 (70) 6/30 (20) 3/30 (10)
1 to 14 days 46/60 (77) 4/60 (7) 10/60 (16)
15 to 31 days 15/21 (72) 3/21 (14) 3/21 (14)
TST $5 mm 51/62 (82) 6/62 (10) 5/62 (8)
,5 mm 22/30 (74) 4/30 (13) 4/30 (13)
QGIT, QuantiFERON-TBH Gold In-Tube; TST, Tuberculin Skin Test.
doi:10.1371/journal.pone.0002489.t002
Table 3. Analysis of patient characteristics to determine association with positive QuantiFERON-TBH Gold In-Tube result.
Univariate Analysis Multivariate Analysis, n=100
n Odds Ratio [95%CI] p Odds Ratio [95%CI] p
CD4
+$200 cells/ml 105 4.71 [1.87,11.83] 0.001 4.68 [1.74,12.60] 0.002
Smear grade 111 1.28 [0.80,2.04] 0.297 1.12 [0.65,1.94] 0.691
Male sex 112 1.60 [0.67,3.78] 0.288 1.10 [0.29,3.07] 0.861
BMI,18.5 102 1.29 [0.53,3.18] 0.574 1.59 [0.58,4.38] 0.368
First TB episode 112 1.29 [0.44,3.73] 0.644 1.22 [0.33,4.46] 0.762
TB treated,2 weeks 111 1.17 [0.40,3.36] 0.777 1.71 [0.48,6.18] 0.408
Age.31 years 112 1.20 [0.51,2.81] 0.672 1.13 [0.41,3.10] 0.810
BMI, body mass index.
doi:10.1371/journal.pone.0002489.t003
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range of all other studies in active TB [13], but at a level similar to
other studies in high burden settings [14,15,16]. As previously
observed [14,25], HIV infection was associated with decreased
sensitivity with point estimates for HIV positive and negative
groups being respectively well below and above the pooled
sensitivity. As the sensitivity in the HIV negative patients was
equivalent to those found in low burden countries, this study has
shown that use of QGIT in the clinic setting in Zambia is
technically possible, highlighting the utility of the portable
incubator. There was, however, a significant change in the
performance of the test in the population with CD4
+ counts less
than 100 cells/ml. Using QGIT to diagnose LTBI in Denmark and
in San Francisco, the test was also found to perform poorly when
CD4
+ counts dropped below 100 cells/ml [5,23].
It was expected that immunosuppression, whether due to severe
TB or advanced HIV, would lead to a shift from QGIT positive to
indeterminate results. Surprisingly, in the subgroups with lower
QGIT sensitivity, an increase in not only indeterminate but also
false-negative results was seen, with 20% of HIV positive subjects
receiving a false-negative result.
It is possible that false-positive sputum smears would be
associated with apparently false-negative QGIT. However the
prevalence of non-tuberculous mycobacteria identified by sputum
smear is thought to be very low, especially in high TB prevalence
settings where specificity of a positive smear for MTB is excellent
[26,27]. A second explanation is that of specific anergy due to a
predominance of regulatory TB specific T lymphocytes [28]. This
would be unlikely to affect only HIV positive patients.
An alternative explanation is suggested by looking at the
difference in CD4
+ and CD8
+ counts between those with negative
and indeterminate results. Both CD4
+ and CD8
+ cells can respond
to stimulation with phytoheamagglutin [29], used as the positive
control in QGIT. However, because of their length, the
overlapping peptides used as the TB test antigen are essentially
MHC class II restricted and so only CD4
+ cells respond. Subjects
with low CD4
+ in conjunction with high/normal CD8
+ counts will
therefore react to the positive control but not the test antigen and
generate negative QGIT results, whereas suppression of both cell
lines will lead to indeterminate results. As moderately advanced
HIV is characterised by loss of number and function of CD4
+ cells
but intact antigen presenting and CD8
+ cells [30], and TB is a
feature of advancing HIV disease, this paradigm should be
expected wherever TB and moderately advanced HIV are
prevalent. An alternative positive test antigen targeting specifically
CD4+ cells may eliminate this problem of false-negative results in
such populations.
TST performed reasonably well overall but poorly in HIV
positive subjects and especially in those with low CD4
+ counts.
Both QGIT positive-TST negative discordant results and a
significant number of QGIT negative-TST positive results
occurred. The interpretation of this is impossible within the limits
of this study. The presence of typical BCG scarring did not seem to
affect either test.
In their meta-analysis, Menzies and colleagues draw attention to
the fact that all studies of QGIT to-date have used a cross-sectional
design with many using active TB as a surrogate for LTBI [13].
Acknowledging practical, financial, and ethical reasons why this
approach is so favoured, they emphasise that long-term prospec-
tive trials would be useful to inform the prognostic interpretation
of the IGRA. That is not to say that the cross-sectional approach
Figure 2. T lymphocyte counts by QuantiFERON-TBH Gold In-Tube result. A. Low CD4
+ lymphocyte counts were associated with negative
and indeterminate results whereas B. CD8
+ lymphocyte counts were high in those with negative but low in those with indeterminate results. Box and
whisker plots show range, inter-quartile range and median with dots representing outliers; QGIT, QuantiFERON-TBH Gold In-Tube; * significant
difference, p,0.05 by Wilcoxon rank sum test.
doi:10.1371/journal.pone.0002489.g002
Figure 3. Frequency plot of tuberculin skin test readings
showing QuantiFERON-TBH Gold In-Tube result. Concordance
between TST and QGIT was poor with negative and indeterminate QGIT
results occurring throughout the range of TST results. TST, tuberculin
skin test; QGIT, QuantiFERON-TBH Gold In-Tube.
doi:10.1371/journal.pone.0002489.g003
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with due caution.
As the test is measuring immunity, the diversity in the aetiology
and natural history of disease states, both in terms of mycobac-
terial activity and the host’s immune response, must be considered.
There are clear changes between latent infection and active
disease and differences between smear positive and smear negative
disease. The transition from latent infection to active disease
represents a break down in immune control, similarly smear
negative disease is often associated with more extensive, less well
contained infection than smear positive. Immunity is further
impaired in severe TB possibly as cause or effect, but the patients
in the majority of studies are ambulatory with mild to moderate
disease. On a population level, ethnic differences in immune
response and the effects and prevalence of immunomodulatory
factors such as helminths and non-tuberculous mycobacteria are
unclear [31]. The effect of TB treatment on the immune response
is inconsistent although treatment up to one month was not seen to
have any significant effect in the present study [16]. Interpreting
these data must therefore be done with a clear idea of the
population involved and their disease state. In the present study
the subjects were similar in many ways to those in previous studies,
they were adults with active, smear positive TB of mild to
moderate severity. However, being set in Zambia, it is one of few
studies in a sub Saharan African population with a high incidence
of TB and high prevalence of HIV.
Although it is possible that false-positive smear results could lead
to underestimation of QGIT sensitivity, using positive sputum
smear as a gold standard probably overestimates the true overall
sensitivity of QGIT in active TB. When mycobacterial culture was
used in South Africa, sensitivity in smear negative disease was 65%
compared to 80% in smear positive [14]. This is important as
around two-thirds of patients treated in one of the clinics in Lusaka
were registered with a smear negative diagnosis, the proportion
being even higher in those with HIV (unpublished survey). As we
know that active TB is associated with immunosuppression and
develops via a breakdown of the immune control of latent
infection, directly extrapolating the sensitivity in active disease to
LTBI is conceptually challenging. If we assume that people with
positive results in the active disease state would have had also been
positive in the latent phase, the focus must be on understanding
the causes of negative and indeterminate results.
Conclusions
A tool to improve diagnosis of LTBI could be useful to direct
isoniazid preventive therapy in high burden settings. Present
barriers to the implementation of isoniazid preventative therapy
policies are sited as cost, logistic problems and the difficulty of
excluding active TB [8]. Introducing an IGRA would incur direct
costs and also require considerable logistical and laboratory
resources.
This study has shown that use of QGIT in the clinic setting in
Zambia is technically possible. However, the accuracy of QGIT in
populations with high prevalence of disease remains to be
confirmed. A policy of providing isoniazid preventative therapy
to all people living with HIV therefore continues to be an evidence
based, safe, low-cost option [32]. Further research into IGRA in
high burden settings is required both in terms of prognostic and
programmatic issues.
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